NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis $11.06 +0.10 (+0.87%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Enfusion Stock (NYSE:ENFN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enfusion alerts:Sign Up Key Stats Today's Range$10.99▼$11.1250-Day Range$9.50▼$11.0652-Week Range$7.52▼$11.38Volume2.46 million shsAverage Volume468,870 shsMarket Capitalization$1.42 billionP/E Ratio276.44Dividend YieldN/APrice Target$10.25Consensus RatingReduce Company OverviewEnfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More… Enfusion Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreENFN MarketRank™: Enfusion scored higher than 52% of companies evaluated by MarketBeat, and ranked 403rd out of 665 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingReduce Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on 2 buy ratings, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageEnfusion has only been the subject of 3 research reports in the past 90 days.Read more about Enfusion's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth150.00% Earnings GrowthEarnings for Enfusion are expected to grow by 150.00% in the coming year, from $0.06 to $0.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 276.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 111.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 276.44, which means that it is trading at a more expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 236.90.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 1.58. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 18.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enfusion's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.13% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enfusion has recently decreased by 31.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.13% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enfusion has recently decreased by 31.40%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.29 News SentimentEnfusion has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Enfusion this week, compared to 3 articles on an average week.Search Interest2 people have searched for ENFN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $597,367.00 in company stock.Percentage Held by Insiders36.44% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enfusion's insider trading history. Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Stock News HeadlinesEnfusion, Inc. (NYSE:ENFN) Director Sells $17,237.61 in StockJanuary 16, 2025 | insidertrades.comEnfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,771 SharesJanuary 11, 2025 | insidertrades.comWall St turns to THIS catalyst after Trump’s inaugurationWall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger than his inauguration. As soon as January 29th…January 20, 2025 | Timothy Sykes (Ad)Insider Selling: Enfusion, Inc. (NYSE:ENFN) CFO Sells 24,443 Shares of StockDecember 27, 2024 | insidertrades.comWilliam Blair downgrades Enfusion (ENFN) to a HoldJanuary 18 at 6:28 PM | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of ShareholdersJanuary 16, 2025 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and EDBL on Behalf of ShareholdersJanuary 15, 2025 | globenewswire.comAnalysts Set Enfusion, Inc. (NYSE:ENFN) Price Target at $10.25January 15, 2025 | americanbankingnews.comSee More Headlines ENFN Stock Analysis - Frequently Asked Questions How have ENFN shares performed this year? Enfusion's stock was trading at $10.30 on January 1st, 2025. Since then, ENFN stock has increased by 7.3% and is now trading at $11.0550. View the best growth stocks for 2025 here. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its earnings results on Thursday, May, 9th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by $0.05. The company earned $48.05 million during the quarter, compared to analyst estimates of $47.67 million. Enfusion had a trailing twelve-month return on equity of 6.67% and a net margin of 1.70%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an initial public offering on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's top institutional shareholders include SG Americas Securities LLC (0.02%), Lake Street Private Wealth LLC (0.01%) and Harbor Capital Advisors Inc. (0.01%). Insiders that own company stock include Neal Pawar, Oleg Movchan, Bronwen Bastone, Dan Groman, Matthew Campobasso, Deirdre Somers, Valeria Gutowski, Tarek Hammoud and Stephen Malherbe. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enfusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enfusion investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings5/09/2024Today1/20/2025Next Earnings (Estimated)3/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryComputer Software Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$10.25 High Stock Price Target$13.00 Low Stock Price Target$8.00 Potential Upside/Downside-7.3%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio276.44 Forward P/E Ratio184.25 P/E Growth1.58Net Income$6.03 million Net Margins1.70% Pretax Margin3.64% Return on Equity6.67% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$174.54 million Price / Sales8.14 Cash Flow$0.16 per share Price / Cash Flow68.97 Book Value$0.61 per share Price / Book18.12Miscellaneous Outstanding Shares128,570,000Free Float81,720,000Market Cap$1.42 billion OptionableOptionable Beta0.95 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:ENFN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.